Clinical trials: Ear Noise
Sensorineural Hearing Loss
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.
- Trial name
- NCT04129775
- Testing
- OTO-413
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Otonomy, Inc.
Tinnitus, Hearing Loss, Cochlear Implant Users
Sound Therapy for Tinnitus Relief in Cochlear Implant Users
The aim of this exploratory study is to evaluate the use and effectiveness of sound therapy for tinnitus relief in cochlear implant users with tinnitus.
- Trial name
- NCT03026829
- Testing
- CART sound therapy
- Where
- 2 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- Cochlear
Hearing Loss
CLEAR Clinical Study
Acute in-booth assessment of a new noise reduction algorithm with cochlear implant recipients.
- Trial name
- NCT03126825
- Testing
- CP910/CP920 with noise reduction on, CP910/CP920
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Cochlear
Pulsatile Tinnitus, Venous Sinus Stenosis
BosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous Tinnitus
This study is evaluating the safety and clinical performance of the BosSTENT, a new stent designed specifically for treating pulse-synchronous tinnitus due to venous sinus stenosis.
- Trial name
- B-SILENT (NCT07070089)
- Testing
- BosSTENT implantation
- Where
- 6 sites in Canada, France
- Volunteers
- 90 people
- Sponsor
- Sonorous NV, Inc
Meniere´s Disease
Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease
The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease.
- Trial name
- MD (NCT06765993)
- Testing
- Isosorbide oral solution
- Volunteers
- 234 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Tinnitus
The Akloma Tinnitus Patch in Patients With Manifested Tinnitus
OBJECTIVES: Primary Objective The primary objective will be a decrease of inconvenience with at least 10% for at least 50% of the subjects.
- Trial name
- Aktin (NCT01226108)
- Testing
- Patch
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- Akloma Bioscience AB
Hearing Loss
Benefits of Assistive Listening Device for Speech Intelligibility
Speech intelligibility in noise will be evaluated in adults with moderate to moderate-severe sensorineural hearing loss, using an assistive listening device and hearing aid, and compared to speech intelligibility in noise using…
- Trial name
- NCT05072470
- Testing
- Roger microphone, Phonak Audeo hearing aid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sonova AG
Lung Cancer, Head and Neck Cancer
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3…
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity
- Trial name
- NCT01451853
- Testing
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose
- Where
- United States
- Sponsor
- Sound Pharmaceuticals, Incorporated
Sensorineural Hearing Loss
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.
- Trial name
- NCT04462198
- Testing
- PIPE-505
- Where
- 8 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
OTO-104 for Meniere's Disease
The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.
- Trial name
- NCT01084525
- Testing
- OTO-104 (steroid) 3 mg, OTO-104 (steroid) 12 mg
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- Otonomy, Inc.
Tinnitus
The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception
This study evaluates the ability of compensatory auditory stimulation (CAS) and transcranial direct current stimulation (tDCS) to help alleviate tinnitus.
- Trial name
- NCT02648542
- Testing
- Compensatory auditory stimulation, transcranial direct current stimulation, Combined CAS and tDCS
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Soterix Medical
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Tinnitus, Subjective Tinnitus
Efficacy and Safety of the Soricle for Subjective Tinnitus Relief
This study was conducted to evaluate the efficacy and safety of Soricle, a medical device combining transcutaneous vagus nerve stimulation and sound stimulation, in patients with subjective tinnitus.
- Trial name
- NCT07548320
- Testing
- tVNS Device, tVNS + Sound Stimulation Device
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Neurive Co.,Ltd.
Hearing Loss
Noise Reduction Preferences in Teenagers and Pre-teens
Noise reduction preferences and blue tooth access to hearing aid streaming features will be evaluated in experienced hearing aid users age 10-17.
- Trial name
- NCT05372094
- Testing
- Phonak Hearing Aid
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Subjective Tinnitus
Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
- Trial name
- EASE (NCT00739635)
- Testing
- Neramexane mesylate
- Where
- 54 sites in Austria, Germany and 3 more
- Volunteers
- 411 people
- Sponsor
- Merz Pharmaceuticals GmbH
Hearing Loss
Evaluation of Nucleus 6 Sound Coding Algorithms
The purpose of the study was to evaluate the features of the Nucleus 6 Sound Processor (CP900 series) on existing Nucleus recipients who currently use the previous generation sound processor, the Cochlear Nucleus CP810 (also…
- Trial name
- NCT01854879
- Testing
- Nucleus 6 sound processor
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Cochlear
Hearing Loss, Sensorineural, Noise Induced Hearing Loss
FX-322 in Adults With Severe Sensorineural Hearing Loss
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with severe sensorineural hearing loss.
- Conditions
- Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Trial name
- NCT04629664
- Testing
- FX-322
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Frequency Therapeutics
Chronic Tonal Tinnitus
Clinical Investigation on the Acoustic Stimulation in the Treatment of Chronic Tinnitus
There are many treatments for chronic tinnitus that have been claimed, with varying degrees of statistical reliability. None of those treatments can eradicate the tinnitus completely.
- Trial name
- NCT00927121
- Testing
- Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- ANM Adaptive Neuromodulation GmbH
Tinnitus
Caroverin and Inner Ear Diseases
This trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom.
- Trial name
- NCT01174979
- Testing
- Caroverin
- Where
- Austria
- Volunteers
- 170 people
- Sponsor
- Phafag AG